Ranchers in southern Mexico are struggling against a flesh-eating parasite infecting livestock
In the southern state of Chiapas, which borders Guatemala, the New World screwworm fly's rapid spread appears to have caught most ranchers off guard, despite memories of previous outbreaks in the 1980s and 1990s.
Mexico is building a plant with U.S. support in Chiapas to produce sterile flies , which have proven effective at stopping the spread, but it won't be ready until next year. Meanwhile, the price of medicines used to treat livestock infected with the screwworm have soared in price.
That has led some to fall back on home remedies like applying gasoline or lime to open wounds to coax out the worms.
In addition to the cost of the medicine, treatment requires careful monitoring and usually involves multiple courses. Any open wound, even very small ones, are an invitation to the fly to lay its eggs.
Veterinarian Alfredo Chávez left Chiapas to study in 1989, so he says he missed seeing the effects of that outbreak, but now he's seen cases multiply in his corner of the state over the past month.
He's heard of dozens of cases in the area now and treated about a dozen himself. It's not just cows either — sheep, pigs, cats and dogs are targets as well.
Armed with a pair of blue tweezers and an aerosol spray that helps draw the maggots out, Chávez moves from animal to animal. He puts maggots in plastic tubes as samples, which he provides to agricultural authorities.
But beyond providing the tubes and encouraging ranchers to report cases, he said that the government hasn't provided much help.
'We've faced it alone,' he said Wednesday.
The U.S. had just gradually started to reopen the border to cattle imports this month after an earlier suspension in May , when the Trump administration said that it would close it again after an infected animal was found in the Gulf coast state of Veracruz. While prevalent in Central America, the concern is that the fly is moving north.
U.S. officials worry that if the fly reaches Texas, its maggots could cause large economic losses, something that happened decades ago.
Ranch caretaker Edi Valencia Santos said that Mexican government officials have come to his community to talk to people with livestock, but so far without resources. He has had five infected animals on the ranch.
Despite cattle in this region going to domestic consumption rather than to the U.S., the presence of the screwworm in Mexico has frozen cattle exports to the U.S. nationwide.
Valencia said that he remembers the small planes distributing sterile flies during those earlier outbreaks, so is optimistic they will eventually help, but for now the costs are piling up on ranchers.
'It's a big, big problem in Chiapas,' he said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
3 days ago
- New York Post
Spread of flesh-eating parasite in Mexico puts US on high alert
A flesh-eating parasite spreading across Mexico and Central America has placed the U.S. on high alert, but government officials say several key steps have been taken in case an outbreak occurs here. According to a June report from the USDA Animal and Plant Health Inspection Service (APHIS), the New World screwworm (NWS) is a fly larva that infests the living tissue of warm-blooded animals, including humans, that causes a painful condition known as myiasis. Advertisement According to the Center for Disease Control (CDC), the name screwworm refers to the feeding behavior of the larvae, known as maggots, as they burrow, or 'screw,' into healthy tissue. When that happens, the CDC says extensive damage could occur as the maggots tear into their host's tissue with sharp mouth hooks. That wound can then become larger and deeper as more larvae hatch and feed on the tissue. The USDA said those infestations of NWS can be fatal if left untreated. Where is the New World screwworm now? According to the APHIS, the NWS is currently known to exist in parts of every country in South America except Chile, as well as in parts of the Caribbean. Advertisement The APHIS said Panama reported a dramatic increase in the number of NWS cases in 2023, and since then has spread northward through Central America. 3 New World screwworm (NWS) is a species of parasitic flies that can cause myiasis and feed on live tissue. CDC And in November 2024, the NWS reached the southern state of Mexico. As of the June report, the APHIS said the NWS has not been spotted in the U.S. What's being done to prevent the New World screwworm from entering the U.S.? Advertisement The APHIS said there are two ways officials can try and prevent the spread of the NWS inside the United States. One of the ways is by preventing contact between NWS flies and non-infested animals, including the prevention and treatment of wounds in non-infected hosts, as well as by quarantining and treating infested livestock. Another way to try and prevent the spread of NWS is by stopping the reproduction cycle altogether. This can be done through the detection and treatment of infested animals, and with the use of the Sterile Insect Technique (SIT). Advertisement That technique exposes NWS pupae to gamma radiation to create sterile NWS flies. These are then released into the wild from either ground level or the air, with sterile males overwhelmingly mating with wild female flies that then lay unfertilized eggs. 3 Government officials say several key steps have been taken in case an outbreak occurs here. Rmd17 – The APHIS said that because female NWS often flies only mate with one male during its lifecycle, the population of NWS flies is progressively reduced and then eradicated. How does it spread? The CDC says New World screwworm infestations begin when a female fly lays its eggs on open wounds or on other parts of the body and mostly affects livestock. However, it can also infest birds and humans. The female flies are attracted to the smell of a wound or other opening, and wounds as small as a tick bite could attract the female. 3 Another way to try and prevent the spread of NWS is by stopping the reproduction cycle altogether. Rmd17 – One female, according to the CDC, can lay 200-300 eggs at a time and could lay up to 3,000 eggs during its 10- to 30-day lifespan. Advertisement Those eggs then hatch into larvae and burrow into the host's flesh. What are the symptoms? As we stated above, infestations are very painful. The CDC says some of the symptoms of infestation include (are you ready?) unexplained skin lesions that don't heal, bleeding from open sores and feeling larvae movement within a skin wound or sore, or in the nose, mouth or eyes. An infected host may also see maggots around or in the open wounds.
Yahoo
5 days ago
- Yahoo
Disturbing research reveals alarming disparity in seafood served to tourists and locals: 'Contain potentially hazardous chemicals'
Disturbing research reveals alarming disparity in seafood served to tourists and locals: 'Contain potentially hazardous chemicals' In one Mexican fishing town, tourists dine on lobster while locals are left with microplastic-tainted fish. What's happening? In Puerto Morelos, fishers are risking their lives at sea to catch high-value seafood that ends up on affluent tourists' plates. Meanwhile, as Wired explains, they are left to feed their families with local fish caught near the town's beaches, which are contaminated with microplastics. These anglers also complain about pirates who fish offseason with "total impunity," resulting in a drop in lobster populations. This narrative is supported by a study, published in the journal Marine Biology, that documented these fishers' lives and analyzed contaminants in 424 locally caught fish. Scientists found that fish caught with a simple line and hook in shallow waters near the coast had significantly more plastics in their digestive systems than those caught in deeper waters, Wired noted. Why is this study concerning? This study adds to a mountain of research that has uncovered microplastics in food, water, air, and soil. For instance, one study on different animal and non-animal protein sources found microplastics in nearly all samples, including beef and tofu. While scientists are trying to better understand how microplastic exposure can affect us, these tiny plastic particles have already been tied to health problems such as cancer, dementia, kidney disease, and impaired blood flow in the brain. Still, more research needs to be done to understand the full impacts of microplastics, according to Omar Oslet Rivera-Garibay, lead author of the new study. "Microplastics contain potentially hazardous chemicals, such as plastic monomers and additives, and they absorb toxic contaminants from the environment, like harmful microbes and algae that may cause illnesses in humans," he told Wired. "However, there is still no solid evidence that the safety of seafood is compromised by microplastics." What's being done about microplastics? Microplastics are difficult — but not impossible — to remove from the environment. In fact, researchers in Australia have created an absorbent in the form of a powder additive that attracts microplastics and dissolved pollutants. Another group of scientists has found a way to remove them from farm soil by using a type of processed farm waste. You can help be part of the solution by stopping microplastics at their source. Microplastics most often enter the environment as larger plastics that degrade over time. Simple actions such as using a reusable water bottle, opting for a reusable shopping bag, and bringing your own to-go containers to restaurants can make a big difference. Do you think Americans use too much plastic? Absolutely Only in some states We're getting better We're doing fine Click your choice to see results and speak your mind. Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet.
Medscape
5 days ago
- Medscape
Asthma Care: Must-Know Insights for Primary Practice
Asthma is a respiratory condition that requires individualized care, considering each patient's unique characteristics and therapeutic opportunities. Both primary care professionals and specialists are responsible for managing asthma in both adults and children. The new Manejo Integral del Asma (MIA 2.0) guidelines, based on the best international recommendations and adapted to the Mexican healthcare context, including costs and local realities, are aimed at healthcare professionals across various levels of care. These guidelines highlight the importance of multidisciplinary management and continued efforts to improve asthma care in Mexico and Latin America. The project was led by the Mexican College of Clinical Immunology and Allergy and endorsed by 16 scientific institutions or specialty societies, which manage asthma in fields such as allergy, pulmonology, otorhinolaryngology, emergency medicine, general and family medicine, internal medicine, and pediatrics. The general coordination was carried out by Désirée Larenas-Linnemann, MD, an international expert who represents Mexico for the Global Initiative for Asthma, coordinates the International Severe Asthma Registry, and leads the Center of Excellence in Asthma and Allergy at Médica Sur Hospital in Mexico City, Mexico. In an interview with Univadis Spain , a Medscape Network platform, Larenas-Linnemann emphasized, 'It is important to understand that asthma is an inflammatory process of the bronchial tubes.' This means that prescribing only salbutamol is insufficient, as both maintenance and rescue therapy require dual therapy: one drug to open the bronchi and another to reduce inflammation. Another critical point concerns allergic asthma, which constitutes the majority of cases in both children and adults. In these cases, Larenas-Linnemann recommends co-management with an allergy specialist to apply immunotherapy alongside the specific treatment once symptoms are controlled. Primary Care Challenges in Mexico Larenas-Linnemann noted that many patients who are well treated during an asthma crisis in emergency departments often leave without essential maintenance treatment to prevent future flare-ups. 'Follow-up care is very important,' she emphasized. Abril Daniella Alemán Ortega, DO, pediatrician at the Hospital Regional de Alta Especialidad de Zumpango, Mexico, who did not participate in drafting the guidelines, mentioned that diagnosing and managing asthma is more challenging in children than in adults. However, early management is crucial to prevent these children from developing severe respiratory issues as adults. When asked about common mistakes made by her colleagues, Alemán pointed out the misuse of pharmacologic treatment, often involving incomplete regimens or short-term use. She also noted areas for improvement in medication administration and in providing information to families. Alemán emphasized the importance of the guidelines because they encompass everyone from primary care physicians to subspecialists involved in pediatric care. She also stressed that the primary care doctor must recognize that a patient with recurrent respiratory symptoms likely doesn't have recurrent infections, and that prescribing repeated antibiotics rarely solves the problem. 'This is a good point to review,' she concluded. The guidelines also provide specific recommendations for diagnosing and treating asthma under less-than-ideal conditions. For example, in settings where only beclomethasone and salbutamol are available, specific strategies have been outlined for appropriate use. 10 Recommendations Based on MIA 2.0 Guidelines When to suspect asthma. Suspecting asthma can be challenging due to the varied ways it can present, often without the classic wheezing. However, recognizing key symptoms and understanding their variations make raising suspicion straightforward. The four key signs/symptoms that suggest asthma are cough, dyspnea (shortness of breath), wheezing, and chest tightness. If two or more of these symptoms are present, particularly with variation in time, intensity, and exacerbation with environmental factors (such as exercise, laughing or crying, temperature or humidity changes, or allergen exposure), asthma should be suspected. The likelihood of asthma increases if these symptoms are frequent or worsen at night or in the early morning. What doesn't help in diagnosis. Chest x-rays are generally not useful for diagnosing asthma because they typically do not show changes outside of an acute asthma crisis. They are only useful for excluding alternative diagnoses. In patients with well-controlled asthma who are symptom free, spirometry results are usually normal. While spirometry with classic abnormalities confirms asthma, a normal result does not rule it out. What helps. Clinical manifestations should be combined with respiratory function tests that demonstrate airflow obstruction, particularly during exhalation and its variability. Useful tests include spirometry before and after administering a bronchodilator, peak flow measurement over 5-15 days, oscillometry before and after bronchodilator administration, and, in rare cases, bronchial challenge tests. When possible, especially if pulmonary function tests are inconclusive, testing for positive type 2 inflammation biomarkers is recommended because most asthma cases involve type 2 inflammation. In children younger than 5 years, pulmonary function tests are limited, and symptoms are often linked to other age-specific conditions. However, between ages 2 and 3, a subgroup of children who will have poor long-term outcomes can be identified, and by age 5, these children typically show significant reductions in lung function. A specific tool, the Asthma Predictive Index, can help predict which preschool children with wheezing will likely develop asthma. If symptoms are highly suspicious, a therapeutic trial should be performed to assess response. After confirming the diagnosis, categorize the disease. Define the level of asthma control. The Asthma Control Test includes five simple questions about symptoms and medication use over the past 4 weeks, allowing patients to evaluate their own control. Versions are available for both adults and children. Individualize treatment by assessing future risk, severity, phenotype, and endotype. For example, in suspected allergic asthma, skin or serum tests with allergens should be conducted to confirm sensitization. What if a full assessment isn't possible? A positive clinical response to a therapeutic trial is a strong indication of asthma. This means symptom improvement with low-dose inhaled corticosteroids and a rapid-acting bronchodilator, administered as needed, for at least 4-6 weeks, with symptoms worsening upon discontinuation. Avoid prescribing diets without justification. Patients with asthma and documented food allergies are at a higher risk for complications. If food allergies are suspected, a diet free of the specific allergen should only be prescribed after confirming the allergy through the presence of specific immunoglobulin E levels. Unnecessary dietary restrictions should be avoided because they can lead to nutritional imbalances. Define medications and devices. In addition to selecting the appropriate medication — such as bronchodilators, anti-inflammatories, and biologics — it is crucial to choose the right device for drug administration based on the patient's preferences and capabilities. It is important to note that synergistic therapy differs from combination therapy. Synergistic therapy refers to the combination of two drugs in one device, such as inhaled corticosteroids with long-acting beta-2 agonists, which theoretically offers greater efficacy than using the two separately. An example is the maintenance and reliever therapy approach, where a dual inhaler is used for both maintenance and rescue, reducing the frequency of crises. However, salbutamol-ipratropium bromide is not considered synergistic because both are bronchodilators without an anti-inflammatory component. MIA 2.0 includes a treatment algorithm for each age group, integrating maintenance-rescue management blocks, with preferred and alternative options for each of the five treatment steps. Educate the patient: Action plan and rescue treatment. Every asthma patient should have a written action plan outlining what to do when symptoms worsen and the risk for exacerbation arises. A key aspect of rescue treatment is that patients must always have access to an anti-inflammatory (such as a corticosteroid or, potentially, a leukotriene antagonist) and should never rely solely on short-acting beta-2 agonists. Sole use of these can lead to more frequent asthma attacks and increased mortality. For rescue treatment, budesonide-formoterol, or beclomethasone-formoterol, or salbutamol with inhaled corticosteroids in two separate devices is recommended. Managing a patient with severe exacerbation (crisis). Assess whether the patient is experiencing a life-threatening crisis with imminent respiratory failure or has risk factors for fatal asthma. If so, initiate high-dose inhaled bronchodilators, oxygen therapy, and systemic corticosteroids immediately, and transfer the patient to a facility capable of managing a potentially fatal asthma crisis. If a life-threatening crisis or risk factors are ruled out, evaluate the severity of the attack and determine treatment for the first 60 minutes, with reassessment at 1 hour. For patients with oxygen saturation below 94% (at sea level), administer oxygen therapy and inhaled medications via nebulization with pressurized oxygen. If the response is not favorable within an hour, and no more than 3 hours, hospitalize the patient. During an asthma crisis, pulse oximetry and pulmonary function test values are more reliable than symptoms alone. However, these objective measures should always be incorporated into the overall clinical picture. When to refer to a specialist. Children and adults with recurrent respiratory symptoms but a low likelihood of asthma. Difficulty confirming an asthma diagnosis even after a therapeutic trial with inhaled or oral corticosteroids. Patients with asthma and chronic obstructive pulmonary disease, particularly if treatment priorities are unclear, or if they show signs of chronic infection, hemodynamic or cardiovascular issues, or other pulmonary diseases. Persistently uncontrolled or severe asthma with frequent exacerbations — two or more crises per year despite proper inhaler use — requiring step 4 treatment, high-dose inhaled corticosteroids, or long-term use of oral corticosteroids (corticosteroid-dependent asthma). Risk for fatal asthma, including crises triggered by nonsteroidal anti-inflammatory drugs, aeroallergens, food allergens, or anaphylaxis. Patients with severe asthma should be treated in specialized centers with expertise in managing complex cases. Evidence or risk for serious side effects from treatment or symptoms suggesting complications. If moderate-dose maintenance and reliever therapy does not control asthma and the dose of corticosteroid inhalers is increased, refer to a specialist if levels of exhaled nitric oxide or eosinophils are elevated. At-risk groups, including pregnant patients, those suspected of having occupational asthma, patients who frequently utilize healthcare insurance, or those with excessive anxiety from the patient or caregiver. In children aged 5 years or younger, if there is no clear association between symptoms and typical triggers or if there is a lack of response to treatment, delayed growth and development, early onset of symptoms, vomiting associated with respiratory symptoms outside of an asthma crisis, continuous wheezing, hypoxemia unrelated to viral illness, focal pulmonary or cardiovascular signs, clubbing of fingers, a history of hospitalization, or multiple emergency department visits for wheezing within a 12-month period. The MIA 2.0 guidelines were endorsed by the Mexican College of Pediatric Pulmonology, Latin American Society of Respiratory Physiology, National Pulmonology Council, Mexican College of Clinical Immunology and Allergy, and several other medical societies.
